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Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties,
but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still
unknown.
Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of
coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color
doppler ultrasound.
Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide
reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by
18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in
carotid IMT did not correlate with changes in any other variable studied.
Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose
and lipids concentrations.
Trial registration: ClinicalTrials.gov: NCT01715428.
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Liraglutide is a long-acting human glucagon-like peptide-
1 (GLP-1) analog suitable for once-daily administration in
patients with type-2 diabetes (T2DM). Clinical studies
have demonstrated glucose-reducing effects, improve-
ments in pancreatic beta cell function and a low risk of
hypoglycaemic events with this agent [1]. Liraglutide has
also shown favorable effects on inflammatory markers,
such as C-reactive protein (CRP), tumour necrosis factor-
α (TNF-α) and plasminogen activator inhibitor type-1
(PAI-1) [2,3]. Further, liraglutide seems to also have an
impact on diabetic dyslipidemia, reducing total choles-
terol, triglycerides and low density lipoproteins (LDL)-* Correspondence: niabate@utmb.edu
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unless otherwise stated.cholesterol levels, with a concomitant increase in high
density lipoproteins (HDL)-cholesterol [3,4].
These favorable effects of liraglutide on multiple
metabolic pathways may have beneficial effects on ath-
erosclerosis and possibly reduce risk for cardiovascular
disease. However, prospective studies to elucidate the
clinical impact of liraglutide on cardiovascular out-
comes in patients with T2DM, such as the international
LEADER (Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results) study,
are still ongoing [5]. We performed a pilot study to ex-
plore, for the first time, the effects of liraglutide on
carotid intima-media thickness (IMT), a recognized
marker of subclinical atherosclerosis, thus providing a
preliminary view on the potential impact of this thera-
peutic intervention on cardiovascular risk of patients
with T2DM.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients’ baseline characteristics (n = 64)
Age (years) 63 ± 8
Women, n (%) 32 (50)
Diabetes duration (years) 9 ± 8
Smoking habit, n (%) 34 (53)
Past history of cardiovascular diseases, n (%) 0 (0)
Family history of cardiovascular diseases, n (%) 26 (41)
Systolic blood pressure (mmHg) 128 ± 13
Diastolic blood pressure (mmHg) 76 ± 6
Hypertension, n (%) 41 (64)
Dyslipidemia, n (%) 42 (66)
Obesity, n (%) 28 (44)
Diabetic complications, n (%) 16 (25)
Use of anti-hypertensive therapies
Beta-blockers, n (%) 21 (33)
Angiotensin-converting enzyme inhibitors, n (%) 15 (23)
Calcium entry blockers, n (%) 12 (23)
Diuretics, n (%) 20 (31)
Use of lipid-lowering drugs
Statins, n (%) 26 (41)
Fibrates, n (%) 9 (14)
Omega-3 fatty acids, n (%) 12 (19)
Aspirin use, n (%) 8 (13)
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Patients and methods
We studied 64 subjects with known or newly diagnosed
T2DM (32 men and 32 women, mean age: 63 ± 8 years)
who were consecutively referred to our Unit of Diabetes
and Cardiovascular Prevention for a clinical evaluation.
All subjects were on metformin therapy (doses ranging
from 1500 to 2000 mg daily). The project design in-
cluded a medical examination, biochemical analyses and
the eco-color-doppler examination of carotid arteries.
The procedures adopted were in agreement with the
Helsinki Declaration of 1975 as revised in 1983, and
were approved by the Ethics Council of the University of
Palermo. This study has been registered in clinicaltrials.
gov (NCT01715428).
All patients gave informed consent to participate in
the study. At admission they underwent a medical exam-
ination and were excluded from the study if they had
clinical evidence of liver dysfunction or renal failure.
Waist circumference, height and weight were recorded,
and BMI was calculated as kg/m2. Fifty-three percent of
the subjects were current smokers and 64% had hyper-
tension diagnosed by the following: systolic or diastolic
blood pressure, respectively, ≥140 or ≥90 mmHg or
previous pharmacological therapy with antihypertensive
drugs. Forty-five patients were already taking anti-
hypertensive or lipid-lowering drugs, and such medica-
tions were maintained at the same doses until the end
of the study. In details, 21 subjects were taking beta-
blockers, 15 angiotensin-converting enzyme inhibitors,
12 calcium entry blockers and 20 diuretics. Twenty-six
patients were on statins, 9 on fibrates and 12 on omega-
3 fatty acids. Eight patients were taking aspirin. None of
the subjects included in the study had a previous major
cardiovascular event (see Table 1).
Metformin was continued at a fixed dose of 1500 mg
daily, and liraglutide was added subcutaneously at a dose
of 0.6 mg daily for the first 2 weeks, followed by 1.2 mg
daily. Patients were followed up for 8 months.
Biochemical analyses
At baseline and after 4 months and 8 months of therapy,
serum glucose and HbA1c were measured after a 14-
hour overnight fast. Total cholesterol, triglycerides and
HDL-cholesterol were measured by standard enzymatic-
colorimetric methods [6-8], while LDL-cholesterol was
calculated using the Friedewald formula.
Color doppler ultrasound of carotid arteries
B-mode real-time ultrasound was performed at base-
line and after 4 and 8 months of therapy to evaluate
the arterial wall thickness in the carotid arteries. All
the examinations were performed by a single exam-
inator (A.M.P.) using a single sonographer (MedisonSonoAce Pico, with a probe of 7.5-10.0 MHz) in a
blinded manner; it means that the examinator did not
have access to previous scans when follow-up studies
were performed. The ultrasound examination was per-
formed in a standardized manner with fixed angles of
insonation.
As previously reported [9], patients were examined in
the supine position, and each carotid wall or segment
was examined to identify the thickest intimal-medial
site. Each scan of the common carotid artery began just
above the clavicle, and the transducer was moved to
the carotid bifurcation and along the internal carotid
artery. Three segments were identified and measured in
anterior and posterior planes on each side: the distal
1.0 cm of the common carotid artery proximal to the
bifurcation, the bifurcation itself, and the proximal
1.0 cm of the internal carotid artery. At each of these
sites we determined the IMT, defined as the distance
between the echogenic line representing the intimal
blood interface and the outer echogenic line represent-
ing the adventitial junction. The maximum carotid
IMT value was used for analysis and determined as the
mean of the maximum IMT of near- and far-wall mea-
surements of both the left and right side arteries for
each of the 3 arterial segments.
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Statistical analysis was performed using Statview® 5.0
(SAS Institute Inc., Cary, NC, USA). Univariate analysis
was performed using paired t-test, while correlation ana-
lysis was performed using the Spearman rank correlation
method. ANOVA was used to test changes in all evalu-
ated parameters from baseline to 4 months and to
8 months of treatment.
Results
All patients took the prescribed medications without dis-
continuation. Two of the patients developed mild nausea
but continued liraglutide throughout the study. As
shown in Table 2, from baseline to 4 and 8 months of
treatment, carotid IMT significantly decreased from
1.19 ± 0.47 to 1.04± 0.35 to 0.94 ± 0.21 (p = 0.0010), while
there was a non significant reduction in body weight
(from 81 ± 17 to 78 ± 16 to 78 ± 16 Kg, p = 0.44) and
waist circumference (from 105 ± 14 to 102 ± 13 to 102 ±
13 cm, p = 0.36). By contrast, there was a significant de-
crease in fasting glucose (from 8.9 ± 3.8 to 7.1 ± 1.6 to
6.8 ± 1.9 mmol/L, p < 0.0001) and hemoglobin A1c (from
8.4 ± 0.8 to 6.7 ± 0.9 to 6.5 ± 0.8%, p < 0.0001).
Therefore (Table 2), after 8 months of therapy average
body weight decreased by 3 kg, fasting glucose by
2.1 mmol/l, and HbA1c by 1.9% (p < 0.01 for all). Lira-
glutide also significantly reduced total-cholesterol and
triglycerides by 10%, and LDL-cholesterol by 19%, with a
concomitant 8% increase in HDL-cholesterol (p < 0.01
for all). Carotid IMT decreased by 0.25 mm after
8 months of therapy (-21% vs baseline). Yet, no signifi-







Weight (kg) 81 ± 17 78 ± 16* 78 ± 16*§ 0.44
BMI (kg/m2) 30 ± 5 29 ± 5* 29 ± 5*§ 0.28
Waist circumference
(cm)
105 ± 14 102 ± 13* 102 ± 13* 0.36
Fasting glicemia
(mmol/L)
8.9 ± 3.8 7.1 ± 1.6* 6.8 ± 1.9* <0.0001
HbA1c (%) 8.4 ± 0.8 6.7 ± 0.9* 6.5 ± 0.8* <0.0001
Total cholesterol
(mmol/L)
4.4 ± 0.9 4.0 ± 0.7* 3.9 ± 0.7* 0.0020
Triglycerides
(mmol/L)
1.8 ± 0.7 1.6 ± 0.7* 1.6 ± 0.7* 0.26
HDL-cholesterol
(mmol/L)
1.07 ± 0.3 1.09 ± 0.3 1.16 ± 0.3*§ 0.19
LDL-cholesterol
(mmol/L)
2.5 ± 0.9 2.2 ± 0.6* 2.0 ± 0.7* 0.0011
Carotid IMT (mm) 1.19 ± 0.47 1.04 ± 0.35* 0.94 ± 0.21*§ 0.0010
*p < 0.01 vs baseline; §p < 0.01 vs. 4 months.IMT and changes in all the evaluated parameters (data
not shown).
We have further performed multivariate analysis, in
order to assess potential independent associations be-
tween decreased carotid IMT and clinical and laboratory
variables evaluated at baseline. Such baseline parameters
included gender, age, smoking habit, past history of car-
diovascular diseases, duration of diabetes, as well as
plasma HbA1c, LDL-cholesterol, HDL-cholesterol and
triglycerides. We found an independent predective role
for LDL-cholesterol (p = 0.0320) but not for any other
variable examined.
We also investigated the relationship between de-
creased carotid IMT and the use of cardiovascular medi-
cations, including beta-blockers, angiotensin-converting
enzyme inhibitors, calcium entry blockers, diuretics, sta-
tins, fibrates omega-3 fatty acids and aspirin (data not
shown). Yet, we did not find any significant effect for
any of the above-mentioned drugs. Finally, when the ef-
fect of liraglutide on carotid IMT was adjusted for the
use of lipid-lowering drugs, the effect of liraglutide
remained significant (data not shown).
Discussion
This pilot study shows, for the first time, that liraglutide
has desirable effect on carotid IMT in patients with
T2DM after 8 months of therapy. This effect seems to
be achieved by mechanisms independent of induced
changes in plasma glucose and lipid concentrations. This
is somewhat consistent to a very recent study, where
GLP-1 analogue therapy reduced several inflammatory
markers, independently of the glycaemic or body weight
effects induced by the GLP-1 analogue [10]. Pioglitazone
therapy also slowed progression of carotid atheroscler-
osis in subjects with prediabetes, independently of
changes in cardio-metabolic risk factors [11].
Although not yet directly demonstrated, it is possible
that liraglutide has beneficial effects on the process of
atherosclerotic plaque formation. Pre-clinical data have
shown that liraglutide is able to reduce infarct size in
mice with experimental myocardial infarction [12], while
exenatide, a synthetic GLP-1 receptor agonist, reduced
intimal hyperplasia in insulin resistant rats [13]. Further,
in patients with type-2 diabetes, the stimulation of
GLP-1 secretion seems to have a significant impact on
cardiovascular risk [14]. Yet, in a recent study a 6-month
GLP-1 receptor agnist treatment did not modulate vascu-
lar function, despite significant improvements in body
composition and glycaemic control [15].
Regarding other liraglutide effects found in the present
study, body weight significantly reduced after 4 months of
therapy but we found no further change after 8 months of
treatment. In another study [16], liraglutide induced sig-
nificant and persistent weight loss up to 6 months of
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In the present study liraglutide treatment was also able to
significantly reduce plasma total- and LDL-cholesterol
concentrations; further, LDL-cholesterol was the only vari-
able showing an independent associations with decreased
carotid IMT at multivariate analysis. Yet, in a recent study
performed in subjects with type-2 diabetes [17], apolipo-
protein B and not LDL-cholesterol was able to predict
subclinical carotid atherosclerosis.
Further, a large number of our patients were under
cardiovascular drugs; yet, we did not find any significant
relationship between the use of cardiovascular medica-
tions and carotid IMT. This finding may be potentially
explained by: a) the relative small numbers of patients
receiving each individual class of drugs; b) the very com-
mon use in our patients of multiple cardiovascular ther-
apies, which therefore limits the identification of the
effect of a specific class of drug.
Our findings on the beneficial effect of liraglutide on
carotid IMT may be linked to the improved endothelial
function by incretin-based therapies, and GLP-1 in par-
ticular (as reviewed in [18]). Indeed, using different
methodologies, it has been shown that GLP-1 improves
endothelial function in patients with type-2 diabetes or
the metabolic syndrome; such methodologies included
strain-gauged plethysmography and flow-mediated dila-
tion [19-21]. Further, in pre-clinical studies, liraglutide
improved endothelial function and inhibited the progres-
sion of vascular disease via the effects on plaque stability
and endothelial function [22,23].
Previous studies have investigated the effects of anti-
diabetic agents on carotid IMT. For instance, the CHICAGO
(Carotid Intima-Media Thickness in Atherosclerosis
Using Pioglitazone) trial [24] was a randomized, double-
blind, multicenter study, which evaluated the effect of
pioglitazone vs glimepiride on changes in carotid IMT
in patients with type-2 diabetes. In this study, after
18 months of treatment, the change from baseline in
carotid IMT (e.g., the prespecified primary end point)
was −0.001 mm in the pioglitazone group and +0.012 mm
in the glimepiride group. By contrast, in a very recent
study [25], vildagliptin was able to reduce carotid IMT by
about 0.10 mm after only 3 months of therapy in 90 pa-
tients with type-2 diabetes. This finding is somewhat con-
sistent to our finding of a reduction of 0.15 mm after
4 months of liraglutide therapy.
Although our findings regarding changes in carotid
IMT are of considerable interest, the impact of liraglutide
on clinical cardiovascular outcomes is unknown, and fur-
ther studies are needed to investigate its athero-metabolic
actions. The very recent data on the cardiovascular out-
come with the use of saxagliptin and alogliptin highlight
the need of more studies for incretin-based therapies
[26,27], including the GLP-1 analogues. It is hoped thatthe ongoing international LEADER study will provide use-
ful answers in this regard [5].
A limitation of the present study is the lack of the pla-
cebo (control) arm. Such control group had to include
patients undergoing metformin therapy only, e.g. with-
out liraglutide. Although we did not investigate the
effect of metformin alone on carotid IMT, previous stud-
ies have shown that metformin therapy has mild or null
effects on carotid IMT [28-30]. It is therefore unlikely
that metformin was responsible for the strong and sig-
nificant decrease in carotid IMT that we have found
after 4 and 8 months of therapy. Also, it needs to be
highighted that in the present study we administered lir-
aglutide as add-on therapy in patients who were already
receiving metformin therapy. Finally, the statistical ana-
lysis revealed that the effect of liraglutide on several pa-
rameters (including carotid IMT) was very strong and
highly significant; therefore, the probabilty of the occur-
rence of our findings by chance alone is extremely low.
Strengths of the study include the blinded measure-
ments of carotid intima-media thickness as well as the
excellent adherence to treatment. To our knowledge, the
present study is the first one to examine the effects of
liraglutide on carotid IMT.
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